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Background: The most appropriate public health approach to vaccine-associated measles in immunocompromised
patients is unknown, mainly because these cases are rare and transmission of vaccine-associated measles has not
been previously documented. In this case report, we describe Peel Public Health’s response to a vaccine-associated
measles case in an immunocompromised child in Ontario, Canada.
Case presentation: A five-year-old Canadian-born boy with a history of a hematopoetic stem cell transplant three
years previously received live attenuated measles, mumps, and rubella (MMR) vaccine. Over the subsequent 7 to
14 days, he developed an illness clinically consistent with measles. There was no travel history or other measles
exposure. Serology and polymerase chain reaction (PCR) testing confirmed acute measles infection. Following
discussion with pediatric infectious diseases specialists, but prior to the availability of virus sequencing, it was felt
that this case was most likely due to vaccine strain. Although no microbiologically confirmed secondary cases of
vaccine-associated measles have been previously described, we sent notification letters to advise all contacts of
measles symptoms since the likelihood of transmission from an immunocompromised patient was low, but
theoretically possible. We decided to stratify contacts into immune competent and compromised and to deal with
the latter group conservatively by excluding them as if they were exposed to wild-type measles because the risk of
transmission of disease in this population, while presumably very low, is unknown. However, no contacts
self-identified as immunocompromised and there were no secondary cases. Subsequent genotyping confirmed
that this case was caused by vaccine strain measles virus.
Conclusion: The public health approach to contact tracing and exclusions for vaccine-associated measles in
immunocompromised patients is unclear. The rarity of secondary cases provides further evidence that the risk to
the general public is likely extremely low. Although the risk appears negligible, exclusion and administration of
immune globulin may be considered for susceptible, immunocompromised contacts of cases of vaccine-associated
measles in immunocompromised patients.
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While the public health approach to wild-type measles in-
fection in terms of contact tracing, isolation, and post expos-
ure immunization or immune globulin is well described [1],
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reproduction in any medium, provided the ornot clear. Vaccine-associated measles infections that are
clinically indistinguishable from wild-type measles are rare
and have occurred in both healthy and immunocomprom-
ised children [2-6]. Vaccine-associated measles has not been
shown to be infectious, regardless of the immune status of
the index case. Although studies have detected measles vac-
cine virus in pharyngeal and urine samples in immune com-
petent children with a vaccine-associated febrile rash illness
[3,7], to our knowledge, no microbiologically confirmed
transmission to contacts has been documented. It is un-
known, however, if vaccine-associated measles in immuno-
compromised cases changes the potential transmission risk. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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associated measles in an immunocompromised child and
the decisions made by Peel Public Health regarding contact




A five-year-old Canadian-born boy who received a
hematopoetic stem cell transplant (HSCT) at two years
of age and received a dose of live attenuated measles,
mumps, and rubella (MMR) vaccine (Schwartz – GSK)
approximately three years post HSCT. There was no his-
tory of measles exposure nor travel, however by the 6th
day post vaccination, he had developed fever, cough, cor-
yza, and conjunctivitis. On the 9th day post vaccination
he developed a maculopapular rash and on day 14 he
was admitted to hospital with a clinical diagnosis of pre-
sumed measles. Measles IgM and IgG serology, taken
one day after the onset of the rash, was initially negative.
Subsequently, five days after rash onset, measles IgM
and IgG became positive. In addition, measles real-time
reverse transcriptase polymerase chain reaction (rRT-
PCR) testing using an in-house assay targeting the fusion
(F1), hemagglutinin (H1) and nucleoprotein (N3) genes
was positive from nasopharyngeal (NP) swab, throat
swab, and urine [8]. The virus was sequenced using the
World Health Organization standardized method [9]
and revealed measles genotype A, sequence designation
MVs/Ontario.CAN/08.12 [A] (VAC), which is a vaccine
strain. Viral cultures from the NP swab and urine were
negative and the throat swab grew HSV-1.
Contact tracing and exclusion
Measles is a nationally reportable disease in Canada and
health professionals are legally obligated to report mea-
sles to the local public health department [10]. Peel Pub-
lic Health, in Peel Region and located directly west of
Toronto, received a notification from the provincial ref-
erence laboratory about a measles PCR positive naso-
pharyngeal swab, throat swab, and urine sample, as well
as positive IgM and IgG measles serology collected on
the same day. After this notification, details were col-
lected from a Toronto Public Health nurse regarding
symptom onset and risk factors for measles because the
case was hospitalized in Toronto. Given that the stand-
ard provincial case definition excludes those who have
been recently vaccinated, it was initially not clear that
case management and contact tracing should be pursued
[11]. In addition, this patient did not have any epidemio-
logic links to other measles cases. However, we initiated
an investigation since the case was symptomatic and we
could not confidently rule out wild-type measles based
on the initial serologic and PCR testing.Several potential exposure sites where the child had
attended during the infectious period were identified in-
cluding two physician offices, one emergency depart-
ment, a school, an after school playgroup and a school
bus. These exposure sites included 617 contacts identi-
fied from the catchment area of six public health units.
The immune status of the child was not clear due to his
clinical presentation of measles post-vaccination, des-
pite a previously normal immunological work-up de-
tails in a separate case report. As a result the pediatric
infectious disease specialist advised that the usual
period of communicability (four days before to four
days after rash onset) should be extended until all of
his symptoms resolved. Reports of measles in other im-
munocompromised patients have documented prolonged
viral shedding [12,13].
We began contacting the school board and one of the
physician’s offices that the child had attended to gather
the list of exposed contacts that needed to be excluded
based on our usual procedure for wild-type measles.
Subsequently, after discussing the strong likelihood that
this child had vaccine-associated measles with the
pediatric infectious disease specialist, we decided to
change our exclusion criteria. Although we had still not
received the genotyping results to indicate that this was
a vaccine-associated measles case, we proceeded on the
assumption that it was the most likely cause.
We assumed that all immunized individuals and those
with naturally-acquired infection were immune and
would not be excluded. Unimmunized immune compe-
tent individuals were not considered to be susceptible
because transmission of vaccine-associated measles had
not been documented in this group. However, we were
concerned that immunocompromised contacts could de-
velop vaccine-associated measles and decided to exclude
these individuals for the duration of the incubation
period, in the event they developed symptoms of
vaccine-associated measles similar to the index case.
Since our patient was immunocompromised and had
symptoms of classic measles, we postulated he could be
more infectious than other cases of vaccine-associated
measles. By the time we were notified of the case, the time
window to offer immune globulin (Ig) had passed and we
could not offer this to immunocompromised contacts.
We notified all contacts by sending a letter to watch
for symptoms of measles and to seek medical attention
if symptoms developed. We also indicated that those
with immunocompromising conditions (e.g. pregnancy,
immunosuppressive therapy, immunodeficiency) were at
higher risk of acquiring measles and for developing more
severe disease and asked these people to call Peel Public
Health for further advice. We did not receive calls from
any contacts reporting they were immunocompromised
and no secondary cases were reported. Subsequent
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strain measles virus.
Discussion
Vaccine-associated measles cases are rare and only one
clinical case report of possible transmission has been
published to our knowledge [14], however this case of
potential transmission was based on a clinical diagnosis
and was not microbiologically confirmed to be due to
vaccine strain measles virus. It is uncertain if cases have
not been reported because vaccine-associated measles
strains are not transmissible or because of extremely low
infectivity. Alternatively, susceptible contacts of these
cases could have been infected, but were not detected
because they had subclinical disease. Vaccine-associated
mumps in close contacts of children who had received
primary vaccination with MMR have been reported [3]
so transmission of vaccine-associated measles seemed
theoretically possible.
Canada is in the process of documenting measles elim-
ination and the majority of measles cases in Canada are
now imported from measles endemic countries [15].
However, in this case, the child did not have a travel his-
tory or exposure to a known measles case. Given the
very high likelihood that this case was caused by vaccine
strain measles virus (even prior to laboratory confirm-
ation) we decided not to exclude all contacts from the
usual high-risk settings (e.g. school, health care settings
or workplaces). We stratified contacts into immune com-
petent and compromised groups and decided to exclude
the latter group conservatively as if they were exposed to
wild-type virus because the risk of transmission of
vaccine-associated measles from an immunocompromised
case in this population, while clearly very low, theoretically
may not be zero. No exclusions were applied to immuno-
competent contacts.
Given the theoretical risk of an immunocompromised
contact developing vaccine-associated measles, we de-
cided to send a letter to all contacts advising them to
watch for symptoms of measles and indicated that im-
munocompromised individuals should call our public
health department. Self-identified immunocompromised
contacts would be assessed for susceptibility and ex-
cluded from high-risk settings if required, similar to our
procedure for wild-type measles. We could not offer Ig
for these contacts since the six-day post-exposure win-
dow period had passed. If Ig had been a viable option,
this could have been individually considered for im-
munocompromised contacts. However, we did not re-
ceive any calls and there were no secondary cases.
This case supports the belief that vaccine-associated
measles is of very minimal risk to contacts, regardless of
immune status. Indeed, current recommendations from
national immunization advisory bodies, recommend thatclose contacts of immunocompromised patients should
be vaccinated with measles vaccine to protect this vul-
nerable group [15,16]. Rashes after MMR vaccination
occurs in 5% of vaccinees [16] and public health follow-
up of vaccine-associated measles is not necessary [11].
Wild-type measles is one of the most infectious dis-
eases known with a basic reproductive number ([Ro] the
expected number of secondary cases due to an index
case in a susceptible population), estimated to be up to
18 [17]. However, our immunocompromised patient
with documented vaccine strain measles exposed numer-
ous people with no reported virus transmission. None-
theless, the true risk to immunocompromised patients
from a case who is also immunocompromised is un-
known and may not be zero. For immunocompromised
contacts of vaccine-associated measles clinically indistin-
guishable from wild-type measles in an immunocom-
promised patient, we suggest managing these contacts as
if they have been exposed to wild-type measles. Measles
vaccination in immunocompromised patients is gener-
ally contraindicated because of the risk of disseminated
measles vaccine virus infection. For this reason, we
wanted to advise immunocompromised contacts to
monitor for measles symptoms and exclude them from
high risk settings.Conclusions
This case report describes the contact tracing experience
of our public health department in the management of a
vaccine-associated measles case in an immunocom-
promised child. Given the uncertainty in transmissibility
of vaccine virus from an immunocompromised case
exhibiting classic measles symptoms to immunocom-
promised contacts, we decided to exclude this high risk
group since transmission of vaccine-associated measles
to this population was likely very low, but theoretically
possible. There were no secondary cases reported,
confirming that transmission risk is very low. Although
the risk appears negligible, exclusion and administration
of Ig may be considered for susceptible, immunocom-
promised contacts of cases of vaccine associated measles
in immunocompromised individuals.Consent
Written informed consent was obtained from the par-
ents of the patient for publication of this case report. A
copy of the written consent is available for review by the
Series Editor of this journal.
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